Protagenic chair buys 16,634 shares at $0.59
Rhea-AI Filing Summary
Protagenic Therapeutics, Inc. (PTIX) reported an insider share purchase by executive chair and principal officer, as well as director, Armen Garo H. On August 20, 2026, he purchased 16,634 shares of common stock in an open market or private transaction at $0.5898 per share, increasing his direct holdings to 53,533 shares. The filing indicates the Rule 10b5-1 trading plan checkbox was not selected.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 16,634 shares
Net Buy
1 txn
Insider
ARMEN GARO H
Role
EXEC. CHAIR & PRINCIPAL OFF
Bought
16,634 shs ($10K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | COMMON STOCK | 16,634 | $0.5898 | $10K |
Holdings After Transaction:
COMMON STOCK — 53,533 shares (Direct)
Key Figures
Shares purchased: 16,634 shares of common stock
Purchase price per share: $0.5898 per share
Shares owned after transaction: 53,533 shares of common stock
3 metrics
Shares purchased
16,634 shares of common stock
Insider purchase by Armen Garo H on August 20, 2026
Purchase price per share
$0.5898 per share
Price for the August 20, 2026 insider purchase transaction
Shares owned after transaction
53,533 shares of common stock
Direct holdings of Armen Garo H following the reported purchase
Key Terms
Rule 10b5-1, Form 4, open market or private transaction
3 terms
Rule 10b5-1 regulatory
"The filing indicates the Rule 10b5-1 trading plan checkbox was not selected"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
Form 4 regulatory
"What insider transaction did PTIX disclose in this Form 4?"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
open market or private transaction financial
"purchased 16,634 shares of common stock in an open market or private transaction"
FAQ
What insider transaction did PTIX disclose in this Form 4?
Protagenic Therapeutics, Inc. (PTIX) disclosed that Armen Garo H, its executive chair, principal officer, and director, purchased 16,634 shares of common stock on August 20, 2026 in an open market or private transaction at $0.5898 per share.
Was the PTIX insider trade made under a Rule 10b5-1 trading plan?
No. The Form 4 for Protagenic Therapeutics, Inc. (PTIX) shows the Rule 10b5-1 checkbox as not checked, indicating the reported transaction was not affirmed as being made under a Rule 10b5-1 trading plan.
What role does Armen Garo H hold at Protagenic Therapeutics, Inc. (PTIX)?
In the Form 4, Armen Garo H is identified as a director and an officer, with the title EXEC. CHAIR & PRINCIPAL OFF at Protagenic Therapeutics, Inc. (PTIX).
AI-generated analysis. How Rhea-AI works. Not financial advice.
